Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
North Rhine-Westphalia
-
Bonn、North Rhine-Westphalia、ドイツ、53105
- Department of Psychiatry, University of Bonn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy male volunteers
- Right-handed
Exclusion Criteria:
- Current or past psychiatric disease
- Current or past physical illness
- Psychoactive medication
- Tobacco smokers
- MRI contraindication (e.g. metal in body, claustrophobia)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:Oxytocin; 24IU, 15min
Intranasal administration, 24 international units (IU) oxytocin.
Imaging starting 15min after nasal spray administration.
|
|
アクティブコンパレータ:Oxytocin; 24IU, 45min
Intranasal administration, 24 IU oxytocin.
Imaging starting 45min after nasal spray administration.
|
|
アクティブコンパレータ:Oxytocin; 24IU, 75min
Intranasal administration, 24 IU oxytocin.
Imaging starting 75min after nasal spray administration.
|
|
アクティブコンパレータ:Oxytocin; 12IU, 45min
Intranasal administration, 12 IU oxytocin.
Imaging starting 45min after nasal spray administration
|
|
アクティブコンパレータ:Oxytocin; 48IU, 45min
Intranasal administration, 48 IU oxytocin.
Imaging starting 45min after nasal spray administration
|
|
プラセボコンパレーター:Placebo
Placebo nasal spray.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in the amygdala
時間枠:45min after nasal spray administration
|
Magnetic resonance imaging (MRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli of varying intensity. The investigators specifically plan to investigate amygdala response to fearful faces, as this subcortical region has repeatedly been reported to show activation changes after OXT treatment. Dose-test latency varies between the different treatment arms (i.e. imaging starts 15min [arm 1], 45min [arm 2,4 and 5] or 75min [arm 3] after nasal spray administration). |
45min after nasal spray administration
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Ratings of emotional faces
時間枠:45min after nasal spray administration
|
During each trial, subjects are asked to use a button response grip to indicate whether they perceived the depicted face as neutral, fearful or happy. Depending on the treatment arm, ratings are recorded 15min (arm 1), 45min (arm 2,4 and 5) or 75min (arm 3) after nasal spray administration. |
45min after nasal spray administration
|
Questionnaire measurement of mood (PANAS)
時間枠:10 min before and 105 min after nasal spray administration
|
Positive and negative affect is assessed via self-rating questionnaire 'The Positive and Negative Affect Schedule' using a categorical 5 point scale.
|
10 min before and 105 min after nasal spray administration
|
Questionnaire measurement of anxiety (STAI).
時間枠:10 min before and 105 min after nasal spray administration
|
State anxiety is assessed via self-rating questionnaire 'and State Trait Anxiety Inventory' using a categorical 4 point scale.
|
10 min before and 105 min after nasal spray administration
|
Saliva oxytocin concentrations
時間枠:immediately before the nasal spray administration and (on average) 15,40,80 and 105 min after administration
|
immediately before the nasal spray administration and (on average) 15,40,80 and 105 min after administration
|
|
Plasma oxytocin concentrations
時間枠:immediately before the nasal spray administration and immediately after the fMRI experiment
|
immediately before the nasal spray administration and immediately after the fMRI experiment
|
|
Modulatory effects of autistic like traits on neural and behavioral outcome measures
時間枠:screening session, ~7days prior to imaging session
|
Autistic like traits are assessed via Autism Spectrum quotient in a screening session, preceding the testing sessions.
The investigators expect pronounced OXT effects in subjects with high autistic-like traits.
|
screening session, ~7days prior to imaging session
|
協力者と研究者
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
プラセボの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない